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TOTAL WORD COUNT: 13934 
PART A: STUDY PROTOCOL 
WORD COUNT: 1088 
Cerebral Arteriovenous Malformation Presenting With Haemorrhage. 
 
Principal Investigator: Dr Ntethelelo Mjoli 
Supervisors: Associate Professor Allan Taylor and Dr David Le Feuvre 
 
INTRODUCTION 
Cerebral arteriovenous malformations (AVMs) are a congenital disorder where there is a 
fistulous connection between arteries and veins without an intervening capillary bed. They 
can present with hemorrhage (50 %), epilepsy (40 %), focal neurological deficits or may be 
asymptomatic. In patients who present with a haemorrhage the incidence of AVM re-
bleeding is increased from 2-4% / year [1] to 7-11% / year. [2] 
 
Cerebral AVM can be diagnosed on a brain CT scan or MRI scan, brain CT angiogram or 
MRI angiogram but the gold standard investigation is a cerebral angiogram as this shows the 
angioarchitecture of the lesion.  
 
Important factors in deciding whether an AVM is treated include clinical presentation, 
location, size and features such as venous drainage which determine the risk of 
complications. Treatment options include microsurgical excision, endovascular 
neurointervention, radiosurgery or observation. Attempts at cure particularly with larger 
lesions has been associated with a high rate of complications, (6) which has led to a new 
treatment approach where intervention is directed at specific areas in an attempt to reduce 















RATIONALE FOR THE STUDY 
 
Patients who initially present with intracerebral haemorrhage may have an identifiable 
source of bleeding on angiogram which can be a treatment target. (3 – 4) Previous work 
suggests that the re-bleed rate may be lowered if a weak area is eliminated. (5) 
 
HYPOTHESIS 
Patients with cerebral AVM presenting with haemorrhage may have an angiographically 
identifiable bleeding source suitable for treatment. Where treatment is successful the future 
bleeding rate may be lowered. 
 
METHODS 
1. Study design 
Retrospective folder review of patients who presented to Groote Schuur hospital and UCT 
Private Academic Hospital over a 6 year period from January 2005 to December 2010.   
 
2. Subject identification or selection  
Patients will be selected by the Principal Investigator from a neurovascular database that 
includes all patients who underwent cerebral angiography for various disorders.  All patients 
with the diagnosis cerebral AVM will be selected and a folder review performed in order to 
identify those who presented with intracranial haemorrhage.  
 
Brain CT scans will be reviewed by the Principal Investigator and the Neurovascular 
consultants (Professor Allan Taylor and Dr David Le Feuvre) to confirm the presence of 
haemorrhage i.e. intracerebral, post fossa haematoma, intraventricular, subarachnoid 
hemorrhage and acute subdural haematoma.  
 
Cerebral angiograms of patients with a confirmed presentation with haemorrhage will be 
reviewed by the same team of investigators to confirm the presence of an AVM, identify 













Exclusion criteria include: 
i. Any patient with no evidence of haemorrhage on CT Brain 
ii. Patients that presented with haemorrhage but were found to have facial, dural and 
spinal AVM as a source of the hemorrhage  
iii. Children under 11 years of age.  
 
3. Data collection 
Instruments: 
An electronic data capture sheet was designed for collation of data from patient folders, 
Brain CT scans and Cerebral Angiograms.  
 
List of variables: 
Demographic data: gender and age.  
 
Clinical data: date of admission, presentation, presenting clinical features (headache, 
vomiting, seizures, neurological deficit), duration of symptoms and Glasgow Coma Score. 
 
Brain CT scan: date of imaging, site of hematoma, midline shift, cerebral swelling, status of 
the basal cisterns and hydrocephalus 
 
Cerebral Angiogram: location of nidus, size of the AVM nidus, fistula supply, choroidal 
supply, nidus false aneurysm, bleeding point, flow related aneurysm, associated aneurysm, 
number of veins, vein names, deep venous drainage, venous pouch, venous stasis, 
intervention, bleeding site treated, avm cured, angiogram complications.  
 
Intervention: surgery, neurovascular intervention, radiotherapy, complications. 
 
Follow up: date of last follow up, headache, vomiting, seizure, neurological deficit, GCS, 













Collected data will be statistically analyzed. 
 
ETHICS AND COMMUNICATION 
1. Ethics 
The study protocol will be presented to the Surgical Departmental Research Committee 
(DRC) for approval, following which it will be sent to the Ethics committee with a copy of 
the synopsis for Ethics approval.  
 
The data collation will commence as soon as the protocol has been approved. The folders of 
patients that had an AVM on the database will be requested for analysis. The folders will be 
reviewed in the Records Department for safety and to maintain patient privacy.  
 
The radiographic imaging will be requested from Radiology filing. This will be kept safe in a 
locked room that is only available to the research team. The imaging will only be requested 
for a short period to allow the analysis by the research team. The imaging will be sent back 
to records as soon as the review process is finished. The data collated will be entered into the 
electronic data sheet.  
 
Patient confidentiality will be maintained by following a strict protocol. The patient data will 
be entered into a computer immediately. The computer and research data file will be secured 
by a password that is only know to the reviewers. A computerized data sheet will be used to 
prevent having multiple data cards that can be lost with patient information. The patients’ 
names and confidential information will not be used for publication purposes. 
 
2. Reporting and implementation 
The results of the study will be submitted to a peer review journal for publication and will be 
the basis of an MMed thesis. It is also anticipated that the results will be presented at an 














This will be a retrospective study which will be done during working hours. A three month 
leave from clinical duties will be provided by the Department of Neurosurgery.  
There is no funding allocation for the study. 
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PART B: LITERATURE REVIEW 
WORD COUNT: 5588 
BRAIN ARTERIOVENOUS MALFORMATION (AVM)  
 
Outline 
1. AVM definition 






A brain AVM is a fistulous (non-nutrient supplying) connection between the arteries and 
veins of the brain where instead of normal intervening capillaries there is a nidus. The lesion 
is charecterised by an arterial supply which is pial, transmedullary or choroidal. The venous 
drainage follows the normal deep or superficial drainage of the brain. The nidus is a 
collection of vascular channels that are not similar to capillaries, arteries or veins; these are 
located outside the brain parenchyma. The AVM nidus has a varying angiographic 
appearance and may be very fistulous or comprised of small interconnected channels. The 
size of the nidus is variable from a few millimetres to centimetres.  
 
Arteriovenous shunts are classified by the length of time it takes for venous filling once 
arterial filling has occurred. High shunt lesions fill within 2 seconds whereas a low shunt 
nidus fills more than 2 seconds after arterial filling.(1) 
 
THE NATURAL HISTORY OF AVM 
The estimated incidence of AVM in post mortem and clinical studies is 1: 100000(2,3) with a 
prevalence of 18 per 100000. Fifteen per cent of patients with an AVM are asymptomatic 
and will not ever present for medical treatment.(2) The gender distribution ratio is 3:2 male: 
female. Of the patients who are symptomatic 50% will present with intracranial 
haemorrhage, 40% will develop epilepsy and about 10% will have a neurological deficit 












The headache that is associated with an AVM is non-characteristic. The fourth decade is the 
median of symptomatic presentation.(4-6) 
 
Patients that present with seizures can have focal, generalized or a combination of seizures. 
Seizures tend to present in the younger age group. There are a number of factors that have 
been associated with seizure occurrence such as lesion size and supratentorial cortical 
location, feeders from the middle cerebral artery, cortical feeders, venous varix, the absence 
of intranidal aneurysms(7) and location in an arterial border zone.(8) From a physiological 
viewpoint however it is more likely to be as a result of cortical ischaemia with the motor and 
mesial temporal cortex being more susceptible. Although arterial steal is a postulated cause 
of ischaemia in the tissue surrounding an AVM because of the sumping effect of the fistula a 
venous cause is more likely. Venous congestion of cortex remote from the AVM has been 
noted in patients presenting with epilepsy.(9) 
  
Neurological deficits can be as a direct result of the avm compressing eloquent brain tissue 
or as a complication of uncontrolled seizures or avm rupture with resultant haemorrhage and 
brain tissue damage. In some patients however deficits present without these preceding 
problems and this is again likely due to venous hypertension and resultant ischaemia.  
Patients can present with visual field defects, sensorimotor deficits or language deficits.   
 
Most patients will present with a ruptured AVM with resultant intracerebral haemorrhage, 
intraventricular haemorrhage or subarachnoid haemorrhage. There may be patients that 
present with a combination of the above. The haemorrhage can extend into the meninges 
depending on the site of the rupture. Patients presenting with a ruptured AVM have the 
highest risk of morbidity and mortality and close to 80% of patients that present with a 
haemorrhage will have a neurological deficit. The resulting late morbidity and mortality 
however varies widely between studies.  
 
The overall morbidity rate is 2 - 7% for non-ruptured AVM and 23% for patients with 
haemorrhage.(10) The mortality rate associated with a non-ruptured AVM is 4% while that of 
ruptured AVM is between 6 -16%, but this number can be as high as 29%. The risk of 
haemorrhage in a patient with unruptured AVM is between 2 – 4% per year but this is 













Haemorrhage carries a very high risk to the patient with an avm, so attempts have been made 
to identify factors in the AVM that are associated with a high risk for haemorrhage. There is 
no single factor that has been identified that can conclusively be associated with a 
haemorrhage risk. The following are some of the factors that have been identified by 
different authors and they are not in the order of importance.  
 
Several factors have been identified on the venous end of the AVM. A deep venous drainage 
(ventricular drainage, brainstem drainage or Vein of Galen); a single venous exit, since, the 
number of venous exits is inversely proportional to the venous pressure. Venous stenosis that 
leads to increased pressure within the veins and nidus and retrograde flow in the veins 
especially the superior sagittal sinus. 
 
On the arterial supply side of the AVM there are also multiple factors to consider. The 
presence of an aneurysm is considered to be high risk and there are a number of 
classifications for these. Flow related aneurysms are considered to be saccular aneurysms on 
the downstream feeding vessel of an AVM and these are further divided into proximal when 
close to the Circle of Willis and distal if they are closer to the AVM or on the branches of the 
main arterial supply. Intranidal aneurysms are dilatations within the nidus but their 
observation is subjective and based on the quality of angiography, the frame rate used, the 
speed of flow and observer susceptibility. A false aneurysm is associated with a ruptured 
AVM and represents an area of contrast or blood filling within a haematoma. False 
aneurysms are angiographically characterized by a smooth round wall and contrast stasis. 
They are usually seen within the nidus and contrast lingers in them after the rest of the nidus 
has emptied. An associated aneurysm is a saccular aneurysm that is seen on an artery that is 
not feeding the avm these represent a generalized vasculopathy.  
 
Other factors that are related to an increased risk of bleeding are a small sized avm that is 
less than 3cm; advancing age of the patient and patients older than 60 years old who have 
less elasticity of their arteries, which leads to less compliance of the blood vessels.  
Periventricular and transcallosal location of the avm nidus are also risk factors for 
haemorrhage but these lesions are also drained by the deep venous system. This illustrates 
the difficulty of retrospective assessment of angiographic features in patients who have bled 
in that observed features may be a consequence and not a cause. Posterior fossa location of 
the lesion, male gender and previous presentation with haemorrhage increase the risk of 















Computerised Tomography of the brain (CTB) 
For most patients presenting with focal neurological symptoms, the initial radiological 
investigation is CTB. This is usually the first investigation that alerts the clinician to the 
possible presence of an AVM.  
 
A CTB with no contrast will show a hyperdense lesion in the brain if there is associated 
haemorrhage. The hyperdensity may or may not be associated with a mass effect. The lesion 
is usually in an atypical site for a hypertensive haematoma. Localised calcification in the 
brain parenchyma may be the only sign of an AVM. The AVM may appear as a localised 
area of hypodensity with no visible associated vessels.  
 
A contrast CT brain will show a mass of vessels that are not typical for that area of the brain. 
The nidus can show as a hyperdensity with the contrast media. The AVM will show as a ball 
of blood vessels.  
 
The advantage of a CTB is that it is easily accessible, fast and non-invasive unless contrast 
media has to be administered. The CTB will show associated conditions such as 
hydrocephalus, haematoma, cerebral swelling, ischaemic changes and cerebral oedema. 
 
Computerised Tomography Angiography (CTA) 
A high resolution CTA requires a contrast medium to show the vasculature of the brain. An 
AVM will appear as a tangle of vessels and supplying arteries and draining veins will be 
seen running from the nidus. A high resolution CTA is comparable to a Digital Subtraction 
angiogram in diagnosing an AVM but not as good at resolving angioarchitecture because 
arterial and venous phases are overlapped on CTA.  
 
An advantage of CTA is that it can be done immediately if there is a suspicion of an AVM in 
a CTB. This investigation can also show any flow or associated aneurysms when present. 












source of the haemorrhage can be suggested depending on whether there is predominantly 
subarachnoid blood, related to aneurysm rupture, or a parenchymal haematoma adjacent to 
the nidus.  
  
The CTA is highly dependent on the software and the speed of the scanner. It requires a 
contrast medium and is contraindicated in patients that are allergic to contrast medium. The 
presence of hematoma can mask the presence of a nidus. The CTA is not good for lesions 
that are peripherally located in the cortex.  
 
Magnetic Resonance Imaging 
MRI has the advantage of giving good brain parenchymal resolution and the AVM relation 
to gyral, sulcal and deep structures. It will show the AVM as a flow void on T1 and T2 
images. If there is a bleed the age of the hematoma can be learned from the characteristics 
seen on the MRI. A gradient Echo T2 MRI may show haemosiderin staining which is 
suggestive of old haemorrhage that may have been subclinical. An MRA and MRV can be 
done to clearly show the vasculature of the brain. A further advantage of MRI is the ability 
to demonstrate associated thrombosis in the AVM or water changes in the surrounding brain 
as a consequence of venous hypertension. 
 
The limitations of MRI are that it requires the patient to be co-operative because they have to 
lie still for an elongated period of time to get good images without motion artefact. 
Claustrophobic patients may find it difficult to tolerate MRI 
 
Digital Subtraction Angiogram (DSA) 
This is the gold standard of investigation; it is the best in showing the architecture of the 
AVM. The entire vasculature of the brain can be assessed which will bring to light any other 
vascular lesions that may not have been detected on another investigation.  Because of the 
fast frame rate possible on DSA the temporal resolution of flow from arterial to venous 
structures can be separated and weaknesses in the lesion seen. DSA also allows clear 
visualization of brain arterial supply and venous drainage allowing the identification of en-
passage vessels and shared lesion and brain venous drainage.  
 












is performed under general anaesthesia. The test is safe with a complication incidence of 




There are a number of grading systems that have been developed to help determine the 
treatment risk for the management that is planned for the lesion.(26-33) There are no 
histological grading systems that have been developed. The most common grading system 
will be discussed.  
 
Spetzler-Martin Grading(34) 
This grading system was published in 1986 and it has been the most cited grading system 
ever since.(35,36) The grading system was designed for risk assessment when considering 
surgical intervention. The authors conducted a retrospective study to grade an avm and 
associate the grade with patient outcomes. Three elements were looked at that were found to 
be of significance for surgical resection of the AVM’s, AVM size, location in eloquent 
cortex and the presence of deep venous drainage. The authors proposed a 5 -grade system.  
 
Spetzler-Martin Grading score: 
  Points 
Size of lesion < 3cm 1 
3 – 6 cm 2 
> 6 cm 3 
Venous drainage Superficial  0 
Deep  1 
Location Non-eloquent  0 
Eloquent 1 
 
The size of the avm nidus received the most number of points because it is the most 
significant factor when excising an AVM. The size of the nidus is calculated from the 












is difficult to remove because it may span several eloquent areas therefore the risk of damage 
to the cortex is high. Small avm excision was associated with no morbidity. The authors 
propose that the size of the nidus can be indirectly correlated with the number of feeding 
vessels, amount of flow and degree of steal in the lesion. Assessing the nidus size requires 
experience as it is easy to include arterial supply and venous drainage which will falsely 
enlarge the lesion. 
  
The second factor was the location of the avm nidus in relation to the areas that are 
considered to be eloquent. The areas that are considered to be eloquent were those areas that 
leave the patient with a severe focal deficit if injured during the surgery. The authors 
considered the following to be eloquent areas, language centres, sensory and motor cortex, 
visual cortex, internal capsule, thalamus, hypothalamus, brainstem and cerebellar peduncles. 
The proximity to eloquent areas can be judged on radiological imaging, there is no 
confirmatory test (Wada test, functional MRI and Positron emission tomography PET scan 
or brain mapping) that is required to prove the function of the area.  
 
The last factor considered was the draining vessels of the AVM nidus. The drainage system 
was considered to be superficial or deep. The superficial drainage veins were those that drain 
the cerebral cortex including the superi r and inferior sagittal sinuses, in the posterior fossa 
it is all the veins that drain the cerebellar cortex directly into the lateral or straight sinus. The 
deep venous systems are all the veins that drain the ventricles and the brainstem i.e. internal 
cerebral veins and vein of Galen. Deep venous drainage received a point because these veins 
are difficult to ligate and they may retract leading to severe blood loss.  
 




















A grade VI AVM is described as an AVM nidus that is large with a deep venous drainage 
that cannot be excised. A grade 1 lesion is a lesion less than 3 cm that has superficial venous 
drainage and is not associated with eloquent cortex. A grade V lesion is a lesion larger than 6 
cm with deep venous drainage and close to an eloquent area. Morbidity and mortality is 
directly proportional to increasing grade of a lesion.  
 
Spetzler at al believed that the gold standard of treatment for AVM was surgical excision to 
reduce the risk of further haemorrhage; they believed that incomplete surgical ligation does 
not reduce the future risk of haemorrhage. They also believed that the surgery should only be 
performed if it can improve the natural history of the disease.  
 
A number of studies have supported the findings of this grading system indicating that it is a 
suitable grading system when surgical excision of an AVM is the treatment goal.(37-40)  
 
Disadvantages. 
A weakness of the scale is that there can be variability with cortical eloquence and 
anatomical imaging may not accurately define an area of eloquence. There are also areas of 
functional importance that are not classified as eloquent in the SM score. Cortical injury in a 
non-dominant parietal lesion will lead to visiospatial deficits that can be disabling.  
 
The grading system makes no mention of the arterial supply to the lesion. A lesion with a 
high flow fistula can lead to very severe oedema after excision of the nidus. The number of 
arterial feeders and the areas of supply are also important in planning the excision of the 
lesion. Posterior fossa AVMs even if in a superficial location have a higher treatment 
complication rate because of hydrocephalus and the confined access space during surgery. 
This is a further omission in the SM grading. 
 
Because the grading system is so widely used it is often used out of context in many 
publications. The SM score has little relevance when a patient is to undergo radiotherapy or 
endovascular intervention. It is also of little use when considering the natural history of these 
lesions. The classification does not predict the haemorrhage risk for an individual patient. 












account. Lastly it does not further the scientific understanding of the disease because it is 
only an anatomical grading system.(16)  
 
ANGIOARCHITECTURE 
An AVM has three components that have to be considered when looking at the architecture, 
the arterial supply, nidus and venous drainage. The Angioarchitecture is best assessed on the 
digital subtraction angiogram. 
 
The dominant feeding artery is identified by having a large diameter than would be expected 
or when compared to similar region vessels. A feeding artery may have multiple smaller 
feeding arteries close to the nidus, which are minute in size, these may appear as a puff of 
smoke which should not be confused with Moyamoya disease. An enlarged and elongated 
artery identifies it as a high flow artery. The feeding artery may have a saccular aneurysm or 
a pseudo aneurysm (a localized irregular dilation of the artery wall). The feeding artery 
supplies the nidus but it may also supply brain tissue as well (en-passage vessel).  
 
The nidus can have a variable appearance and can range from compact to diffuse. An 
intranidal false aneurysm is possible after a haemorrhage has occurred and is identified by a 
focal, smooth appearance within the nidus with contrast lingering into the venous phase and 
after the rest of the nidus contrast has cleared. A true nidal aneurysm might be detected when 
no haemorrhage has occurred and this would differ from a false aneurysm in that it has an 
intact wall. True nidal aneurysms are harder to define, as it is dependent on the quality of 
angiography and the size threshold that the observer applies when making this diagnosis. A 
false aneurysm clearly represents a weak area with only clot preventing further bleeding 
whereas the significance of a nidal aneurysm is not as clear. The feeding artery and the 
draining vessels can localize the nidus. The size can be worked out during the contrast 
injection. The flow through the nidus is defined as a high flow fistula if contrast leaves the 
nidus within two seconds, it is low a low fistula if the flow through the nidus is more than 
two seconds.(1)  
 
The venous drainage of the nidus will use the normal veins of the area where the nidus is 
localized. A draining vein should only be counted as such if it can be seen to be directly 
exiting the nidus, as opposed to veins that contribute to AVM drainage through reflux from 












close to a venous sinus and the veins are short. The draining vein may have a varix or venous 
pouch. The venous drainage can be from a single or multiple vessels. The vessels can be 
superficial, deep or a combination. The venous drainage with localized stenosis is easily 
identified by contrast stasis in the vessel.  
 
TREATMENT OPTIONS AND DECISION-MAKING 
Haemorrhage is the risk that all patients and treating doctors would like to avoid in the 
treatment of an AVM, as it is associated with the highest morbidity and mortality. The only 
certain way to prevent haemorrhage is AVM cure. As haemorrhage risk remains fairly 
constant at 2-4% per annum the patient age at the time of presentation is a crucial factor. If a 
patient presents at age 65 years their risk of haemorrhage over the next 15 years is 45% with 
an overall morbidity and mortality risk of 7%. Curative treatment is likely to have a higher 
morbidity at this age and therefore conservative treatment would be a better option.(5,41)  
 
In younger patients with a higher lifetime bleeding risk the decision to obtain a cure is 
largely based on the AVM size. This is irrespective of treatment choice because surgery, 
radiotherapy and endovascular cure are more likely to be achieved in smaller AVM’s. 
 
In patients who have an AVM that is too large to consider cure palliative embolisation is an 
option. Any patient presenting with haemorrhage has a higher bleeding risk for at least the 
next 2 years. If an angioarchitectural weakness could be closed in these patients the bleeding 
risk may be reduced to the baseline 2-4% per year again. 
 
A patient that presents with seizures can be commenced on medical treatment and expectant 
management. Medication will be adjusted according to patient response. If the patient is well 
controlled on medication then the patient can be followed up.  
 
Patients that present with headaches and non-specific symptoms can be managed 
symptomatically. If the symptoms improve then the patient can be followed up. If the 
symptoms do not improve but they are not disabling the patient can be followed up closely. 
 
A patient that presents with focal neurological signs has to be investigated to establish the 












be as to how disabling is the deficit. Patients with a good Rankin score have to be observed. 
If the oedema is the cause then medical therapy can be instituted to improve the oedema.  
 
A patient presenting with haemorrhage will need treatment for any urgent conditions for 
example hydrocephalus, mass effect or herniation. The AVM can be managed electively 
once these urgent conditions have been treated. Three options are available for the AVM, 
these will be discussed briefly but emphasis will be on endovascular treatment. 
 
Surgery 
Surgery offers patients the highest chance of cure when appropriate patients are selected. As 
surgery carries incremental morbidity and mortality with the increasing grade of the AVM it 
is most suitable for low SM grade lesions. Surgical management of SM Grade I and II is 
associated with a morbidity rate of 6 – 8%.(40)  
 
Radiotherapy 
Radiosurgery is a good option for small deep AVM’s as it offers a good cure rate with low 
morbidity. Radiosurgery is done under local anaesthetic with no possible complication of a 
general anaesthetic. The procedure is done in one day. The disadvantage is that it takes up to 
two years before the AVM reduces in size. Radiosurgery is not a good choice in patients 
who have presented with haemorrhage because of the increased bleeding risk. Patients with 
bleeding may benefit from targeted embolisation prior to radiosurgery. Lesions that are 
above 12ml in volume are not suitable for radiotherapy as they carry a high morbidity and 
mortality due to radiation spread into normal tissue.(42) 
 
Endovascular treatment 
Neuroendovascular treatment can be performed for complete occlusion of the avm, partial 
targeted occlusion of the areas that are considered to be weak area and preoperative 
embolisation to reduce the size of the avm before surgery or radiotherapy is instituted.  
 
The role of curative embolisation is to obliterate the AVM and restore the normal arterial 
supply and venous drainage of the brain. The right setting is an AVM less than 3cm, less 
than 3 feeding arteries and the nidus must be accessible with a catheter. Procedure related 












Preoperative embolisation is used to reduce the size of the nidus and decrease the amount of 
blood loss during surgery. It is carries 2 - 4% mortality rate and 9% permanent neurological 
deficit. Le Feuvre et al in their prospective study found a 1.2% death rate and a 6.5% 
permanent neurological deficit.(9) 
 
Partial targeted embolisation therapy (PTET) is used to occlude and reduce the size of the 
AVM with minimal morbidity. The advantage of PTET is that it can be used for any size of 
the AVM nidus. Partial embolisation leads to total obliteration of a flow associated aneurysm 
in 8% of cases where the nidus is reduced by 50%. The morbidity associated with PTET is 
between 4.5 - 13% and the mortality is 1 - 3.5%.(44,45) 
 
There are multiple forms of embolisation, n-butyl-cyanoacrylate glue (NBCA), Onyx and 
silk sutures. 
NBCA glue is injected through a small lumen micro-catheter that can reach the distal 
location of the AVM. The material polymerizes quickly. The procedure requires an 
experienced operator as proximal occlusion may occur and the microcatheter may glue 
against a vessel wall. If the procedure is not correctly performed there may be 
revascularization of the nidus with small arteries that cannot be embolised. There is a limited 
amount of glue that can be used per catheter therefore multiple catheters may have to used to 
get occlusion of the nidus.(46)  
 
Onyx is an embolic material made of ethyl-vinyl copolymer dissolved in dimethy-sulfocise 
(DMSO) with tantalum powder added for radio-opacity. The solidification process is slower 
than with NBCA. Onyx is associated with 3.7% morbidity and 1.4% mortality per session 
embolisation. Complete occlusion of the AVM with Onyx is associated with 8% morbidity 
and 3% mortality on all patients.(45,47)  
 
Embolization with silk sutures involves the use of pieces of 6-0 silk sutures. Silk sutures are 
injected into the feeding pedicles leading to occlusion of the artery. This is associated with 
inflammation of the artery and occlusion of the artery. Studies have failed to show an 
increased incidence of vasculitis with silk sutures.(48-50) The use of silk is however limited as 
occlusion tends to be proximal leaving the nidus intact. 
The complications of embolisation include the rupture of feeding pedicles resulting in 












side contamination with glue leading to venous thrombosis and nidus congestion. The micro-
catheter may get stuck against a blood vessel, with the risk of later thromboembolic 
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AVM patients who initially present with intracerebral haemorrhage may have an identifiable 
source of bleeding on angiogram, which can be a treatment target. Previous work suggests 
that the re-bleed rate may be lowered if a weak area is eliminated. 
 
Methods: 
A retrospective cohort study was conducted of patients that presented over a 6-year period 
with a bled AVM. We were looking for the source of the haemorrhage by applying a strict 
criteria looking at radiological imaging (CT brain, CT angiogram, Digital subtraction 




One hundred patients presented with a brain AVM with a 1.7:1 male: female ratio, 41 
patients had an initial presentation of haemorrhage. The source of haemorrhage was 
identified in 18 subjects with 11 intranidal false aneurysms, 5 flow related aneurysms, 2 
associated aneurysms and 1 venous pouch. The location of haemorrhage on presenting scan 
significantly correlated with the identified bleeding source using Chi-square analysis (chi-
square 16.25, correlation 0.52 and P-value 0.039). Partial targeted embolization was used 
successfully in 90% with 9% related morbidity with no mortality. Long-term follow-up data 















Aneurysms can be identified as a source of haemorrhage in half the patients with AVM. 
Patients are likely to have subarachnoid haemorrhage than intracerebral haemorrhage. The 
weak point is a good target for partial endovascular treatment and it may reduce the re-
bleeding rate over the next 2 years. 
 
KEYWORDS: Arteriovenous malformation  Intranidal aneurysm  
 Partial targeted embolisation 
 
INTRODUCTION 
A brain arteriovenous malformation (AVMs) is a fistulous connection between arteries and 
veins without an intervening capillary bed. They can present with hemorrhage (50%), 
epilepsy (40%), and focal neurological deficits or may be asymptomatic. In patients who 
present with a haemorrhage the incidence of AVM re-bleeding is increased from 2-4% / year 
to 6-18% / year.(1-6) 
 
The ideal treatment of an AVM is complete obliteration of the lesion which removes the risk 
of further haemorrhage and reduces the seizure risk. This is however not always possible at 
an acceptable risk. 
 
Important factors in deciding whether an AVM is treated include clinical presentation, 
location, size and features such as venous drainage, which determine the risk of 
complications. Treatment options include microsurgical excision, endovascular neuro-
intervention, radiosurgery or observation. Attempts at cure particularly with larger lesions 
has been associated with a high rate of complications,(7-14) which leaves an alternative 
approach where endovascular intervention is directed at specific angiographic target areas in 
an attempt to reduce the associated morbidity.(3,15,16) In this study we sought to find a clear 
correlation between presenting with a haemorrhage and having an identifiable angiographic 
bleeding source. Although we may be finding something that is a consequence rather than a 
cause of bleeding it allows more certain correlation between bleed and lesion. As AVM 
haemorrhage rate is significantly increased after a bleed it also offers an opportunity to lower 













SUBJECTS AND METHODS 
The Neuro-endovascular database is an ongoing prospective project collecting clinical and 
neurovascular notes of patients admitted to Groote Schuur and UCT Private Academic 
Hospital. All new AVM patients are captured as well as any subsequent symptomatic events 
that patients may present with. 
 
Subjects were selected from the database if they were presenting for the first time and had an 
arteriovenous malformation presenting with haemorrhage. Patients identified as having a 
dural AVM, facial AVM, spinal AVM or aneurysms with no associated AVM were all 
excluded. A retrospective folder review was conducted to find the demographic and clinical 
data of the subjects. All subjects had undergone a CT brain scan that identified the 
hemorrhage. A consensus review of all the scans was conducted by the authors to identify 
the location of the hemorrhage (intracerebral, subarachnoid or intraventricular) and 
associated findings such as, cerebral oedema, mass effect and hydrocephalus. The 
haemorrhage site was then compared to the digital subtraction angiogram to identify the 
source of the bleeding.  
 
The source of bleeding was identified by looking for the presence of an aneurysm or a 
venous pouch. A flow related aneurysm was defined as a downstream saccular aneurysm in a 
vessel supplying the nidus and an intranidal false aneurysm was identified as a defect with a 
smooth wall that was larger than the nidus channels with contrast lingering within the defect 
into the late venous phase. Nidus irregularities that did not demonstrate all these features 
were ignored as the identification of a nidal aneurysm other than a false aneurysm is 
subjective relying on DSA quality, timing and observer opinion. An associated aneurysm 
was defined as a saccular aneurysm located away from the vessels supplying the nidus. A 
venous pouch was a localised eccentric dilation of a vein draining the nidus.  
 
The angiograms were also assessed for location and size of the nidus, fistulous and choroidal 
supply, the number of draining veins and deep venous drainage. The angiograms and 














Follow up data was collected from folders. A telephonic interview was also conducted to 
assess the clinical status of the subjects with particular interest on the: current level of 
function, presence of headaches, seizures, residual focal deficits and history of rebleeding. 
 
RESULTS 
In the review period 100 new subjects presented with a cerebral AVM. The group that 
presented with hemorrhage was comprised of 41 subjects who collectively had 44 episodes 
of hemorrhage, rebleeding will be discussed later in the results.  
 
The demographic profile of the patients is analyzed in Table 1. Subjects presented with a 
sudden severe headache in 61% of cases and 10 subjects (22%) presented with a generalized 
or focal seizure as a result of their haemorrhage. There were 21 (47%) patients that presented 
with focal neurological deficits ranging from dysphasia, memory loss, and long tract signs. 
The average age of the subjects was 36,2 years with a distribution of 11 to 62 years. The 
median Glasgow Coma Score at presentation was 13 and there were no patients that died on 
arrival or during admission. 
 
The location of haemorrhage on the presenting scans, intracerebral haemorrhage, 
intraventricular hemorrhage or subarachnoid hemorrhage, significantly correlated with the 
identified bleeding source using Chi-square analysis (Table 2). Nine patients presented with 
SAH and of these 5 had bleeding from an aneurysm distant from the nidus, only 2 patients 
with nidal rupture developed significant SAH. Twenty-eight patients had a parenchymal 
haemorrhage associated with the nidus and in 17 of these patients no bleeding point was 
visualized, however of the 11 where a weakness was found, 8 had an intranidal false 
aneurysm.  
 
The source of bleeding (Table 3) was identified in 18 subjects with 19 episodes of 
hemorrhage. Eleven of the patients had a clear intranidal rupture with a false aneurysm 
visible on DSA done shortly after presentation. Eight patients did not bleed from the nidus, 5 
bled from a flow related aneurysm, 2 from an associated aneurysm and 1 from a venous 
pouch. The patient that presented with a repeat bleed, had a right parietal AVM that initially 
presented with SAH and a ruptured flow related aneurysm was identified on the Anterior 
Communicating Artery, the aneurysm was wide necked and it was not amenable to 












source of the bleeding could be found, so he was managed conservatively, he presented after 
4 years with another intracerebral hematoma, an intranidal aneurysm was identified and 
treated, he has not bled since.  
 
All the subjects with an identifiable source of hemorrhage were managed with targeted 
endovascular treatment and this was successful in 89% of the cases. There was a 10,5% 
procedure related technical complication rate, one patient had glue reflux with no clinical 
consequences and the other had thrombi-embolic occlusion of the left MCA branch with 
transient dysphasia, there was no long-term morbidity related to the procedure. The 
procedure had to repeated on some patients in order to achieve the targeted result. There was 
no mortality related to the procedure.  
 
Surgical intervention was performed in 8 (18%) of the subjects following hemorrhage; this 
was for mass effect and hydrocephalus. There were two subjects that had an evacuation of 
the intracebral hematoma and excision of the residual AVM. Only one patient had 
evacuation of intracerebral hematoma and the AVM was left insitu. The remaining 5 patients 
were surgically treated for hydrocephalus, 4 patients had an external ventricular drain on 
admission and it was later removed when the hydrocephalus improved, only one patient had 
an EVD done on admission and later had an Endoscopic Third Ventriculostomy for 
permanent CSF diversion. There were no recorded adverse effect related to the surgery and 
there was no mortality as a result of the surgery.  
 
Long-term follow-up data was only available for 29 patients as some patients were referred 
from far away and were not contactable. 1074 months of patient follow up were completed 
for this cohort (mean of 34 months). Only one patient had rebleeding during this period and 
bled on 2 separate occasions giving an annual haemorrhage rate of 0.7% 
 
DISCUSSION 
Arteriovenous malformations present with haemorrhage in 50% of cases, this accounts for 
2% of all patients that present with stroke.(17,18) There is an equal gender distribution of all 
patients that have an avm, but there are slightly more male patients than females who present 
with a haematoma.(19) Multiple factors have been found to be associated with an increased 
risk of haemorrhage such as a single draining vein, deep seated avm location, small size 












annual risk of a haemorrhage in a patient with an unruptured avm is 2-5% / year with annual 
morbidity and mortality rate of 2,7%% and 1% respectively.(1-3,19) The ruptured avm 
rebleeding risk is 6%-18% within the first year and it lowers to 2% per year for the next 20 
years.(29) This is most likely because the rupture point remains weak and susceptible to re-
haemorrhage until vascular repair is complete. 
 
For AVM’s presenting with haemorrhage the primary treatment objective remains exclusion 
and cure of the AVM and associated vascular weaknesses. This is however not possible in all 
cases as sometimes the AVM is too large or the lesion is inaccessible. Even in patients where 
cure is possible by surgery or radiosurgery, exclusion of the recent bleed site is 
advantageous. In the case of surgery it makes haematoma drainage possible without the need 
to urgently exclude the AVM, which can be operated on electively. In patients who require 
radiosurgery it could reduce the high bleed risk that the patient faces in the next year or two 
to a safer level. 
 
Partial targeted embolisation is a safe alternative to complete excision or occlusion of an 
avm and a useful adjunct even when these treatments are planed. In patients that present with 
haemorrhage, a localised area of weakness representing the rupture point can be identified in 
some patients(9) had a cohort of nine patients that had intranidal aneurysms, which were a 
treatment target. The one-year follow-up of these patients showed a lower rebleeding rate 
than expected.(15) In this study we sought to analyse in more detail the group of AVM 
patients presenting with haemorrhage. 
 
We had one hundred patients that presented with a brain avm over a 6-year period and only 
41 patients initially presented with haemorrhage. These numbers are small but the 
distribution of the patients that presented with haemorrhage is consistent with the natural 
history so this sample is likely representative of a larger AVM population. 
 
It has been previously shown that the location of hemorrhage could not be used to predict the 
presence of an aneurysm.(29) In our cohort, patients that presented with a subarachnoid 
hemorrhage were more likely to have bled from a flow related or associated aneurysm and 
patients presenting with intracerebral bleeding more likely to have a nidal false aneurysm. 
Based on this finding AVM patients who present with SAH should be carefully investigated, 













We were unable to conclusively identify the source of haemorrhage in 25 out of 44 bleeding 
episodes (57%) which is disappointing. We did however apply strict criteria when reviewing 
the presenting scans and angiograms. There had to be good correlation between the 
haemorrhage site and the angiographic weakness and we only identified intranidal false 
aneurysms as a nidal bleeding source. Although other nidal irregularities were observed, and 
some were even called nidal aneurysms in procedure notes, we ignored these lesions because 
they could not definitely be identified as the bleeding site. Nidal aneurysms have been 
associated with a higher haemorrhage risk.(6,7,25) However there is currently no clear evidence 
that it is the nidal aneurysm that ruptures when this patient group presents with haemorrhage.  
 
Other authors have identified flow related and associated AVM aneurysms as a sign of 
vessel fragility, as this group of patients has a higher haemorrhage rate, although the source 
of bleeding was not felt to be aneurysmal.(5,6,15) In our series, five episodes of bleeding out of 
44 were identified as aneurysmal in origin. Given that only 7 patients in this study were 
identified as having flow/associated aneurysms our findings offer a different perspective and 
perhaps avm related aneurysms should be considered as a bleeding source. 
 
We use Neuroendovascular embolisation as our first line of treatment for patients that have 
an identified angioarchitectural target. All patients that presented with haemorrhage were 
embolized with NBCA, one patient was treated with Onyx and there were no patients that 
were treated with particles or silk sutures. NBCA has been shown to effectively occlude avm 
feeders and the avm nidus.(7,30-34) Only one patient had a craniotomy to evacuate the 
haemorrhage because of mass effect, but one patient had an avm excised after embolisation, 
this was a small avm associated with a large hematoma.  
 
Partial targeted embolisation was our treatment of choice for all those patients that had an 
intranidal false aneurysm. All of patients with an intranidal aneurysm could have a catheter 
passed up to or into the nidus and the false aneurysm was occluded successfully. This was 
done in one session for all this group of patients. The flow related aneurysms were all easily 
accessible on the avm feeding artery and all patients were treated using bare platinum coils 
except for one patient who had a wide necked anterior communicating artery aneurysm that 
could not be embolized. This aneurysm was thought to be the source of bleeding in this 
patient and was the only patient where the target could not be treated.. In this patient an 












50%. This patient was the only one to rebleed in the series with an identifiable cause of 
bleeding..  
 
Although follow-up data was not complete for all patients the rebleed rate of 0.7% was 
significantly lower than would be expected for patients presenting with haemorrhage. 
 
CONCLUSION  
Flow related and associated aneurysms in patients with brain AVM can cause haemorrhage. 
These patients are more likely to have SAH than intracerebral haemorrhage.  In just under a 
half of patients with AVM bleeding a source of haemorrhage can be identified on DSA. This 
weak point is a good target for partial endovascular treatment is usually accessible and may 
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Total 63 37 






































SAH 4 2 1 0 2 
IVH 0 1 0 0 6 

















5 (11,3) 4 1 
Intranidal false 
aneurysm 
11 (25) 11 0 
Associated 
aneurysm 
2 (4,5) 1 1 















Patient 1. A 60 year old patient presenting with SAH 20 years after failed surgery for a large 
right parietal AVM. Haemorrhage is mostly in the supra-sellar cisterns and peri-
mesencaphalic cisterns. There is hemispheral cistern blood but no parenchymal blood that 















Patient 1. A CT angiogram revealed a right P1 proximal flow related aneurysm 



















Patient 2. A 14 years old female presenting with sudden onset of headache. A CT angiogram 




















Patient 2.  An intranidal microcatheter injection shows filling of the targeted false aneurysm 
which was closed with an NBCA glue injection. Post embolisation angiography shows no 
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1 No No Yes Yes No No 1 Vermia
n vein 
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27 
A
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Bled	  AVM	  CT	  Brain	  
Site Of Haemorrhage Midline Shift Swelling Basal Cisterns Hydrocephalus 
Interhemispheric SAH Yes Yes Patent No 
Right IVH Yes Yes Patent Yes 
Right Parieto Occipital No Yes Patent No 
Crural Cistern SAH No Yes Patent Yes 
Right Frontal Yes Yes Effaced No 
Right Thalamus With IVH Yes No Patent No 
Left Cerebellar And Vermis No Yes Effaced Yes 
Right CP Angle No Yes Patent Yes 
Left Deep Frontal  Yes Yes Patent No 
Left Parietal No Yes Patent No 
Right Parietal No Yes Patent No 
Left Occipital ICH & L F-T-P 
ASDH, IVH 
Yes Yes Effaced No 
IVH No Yes Effaced Yes 
Left Fronto Parietal With IVH No No Patent No 
Right Cerebellar  No No Patent No 
SAH Midbrain Into Left 
Cerebral Peduncle 












Site Of Haemorrhage Midline Shift Swelling Basal Cisterns Hydrocephalus 
Left Parietal With IVH Yes Yes Effaced No 
Left Temporal Lobe Yes Yes Effaced No 
Left IVH No Yes No No 
Right Basal Ganglia No No Patent No 
IVH No Yes Effaced Yes 
Left Thalamus And IVH No Yes Patent Yes 
Right Frontal With IVH Yes Yes Patent Yes 
Left Lateral Ventricle 
Haemorrhage 
No Yes Effaced Yes 
Right Frontal With IVH Yes Yes Effaced Yes 
Interhemispheric SAH No Yes Patent No 
Left Cerebellar Hemisphere No Yes Effaced No 
Right Occipital Horn No No Patent No 
Left Post Temporo Parietal No No Patent No 
Right Medial Temporal Lobe No Yes Patent No 
IVH No Yes Patent No 
Right Frontal Lobar Yes Yes Patent No 
Prepontine No No Patent No 












Site Of Haemorrhage Midline Shift Swelling Basal Cisterns Hydrocephalus 
Prepontine SAH No Yes Patent Yes 
Left Occipital  No No Patent No 
Left Cerebellar Vermin No No Effaced No 
Right Basal Ganglia No No No No 
Right Parietal No No Patent No 
Left Frontal Yes Yes Effaced No 
SAH Right Sylvian Fissure No No Patent No 
Right Frontal Yes Yes Effaced No 
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2010 
2010 False Nidal Aneurysm 
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Changes 












67 M 0 No No No Right 
Hemiparesis 
Resolved 



























































4 M 0 No No No Memory And 
Visual 
Impairment 







































10 M 0 Yes No No No 15     
  10 Jul 
2008 
14 M 1 Yes Yes No Left Arm 
Monoparesis 






19 M 0 Yes Yes No Left Hemiparesis 15 0 1 
16 Jan 
2007 






43 M 0 No No No No 15 For Radiotherapy 0 
22 May 
2006 
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Right Ear 






25 M 0 No No No No 15 0  
 
 
